Pulmonary Artery Denervation Starts to Show Results

Pulmonary artery denervation is associated with significant hemodynamics improvement, as well as improved clinical outcomes in patients with both post and precapillary pulmonary hypertension. Even though there are several studies on this technique, they included few patients (with different criteria and different devices), which is why we need more randomized studies.

This prospective, randomized, study with sham procedure (following the latest trend) seeks to show the benefit of renal denervation in a combined population of patients with both pre and post capillary pulmonary hypertension.

 

It included 98 patients with pulmonary hypertension defined as mean pulmonary artery pressure mean ≥25 mmHg, a pulmonary capillary wedge pressure >15 mmHg and a pulmonary vascular resistance >3.0 wood units.

 

Patients were randomized to sildenafil plus sham procedure vs. pulmonary denervation. Both groups received standard medical therapy for cardiac failure.


Read also: Revascularization in Patients with Multivessel Disease, Diabetes, and Kidney Disease.


Primary end point was primary endpoint was increase in 6-minute walk distance at 6-month follow-up, and secondary endpoint was pulmonary resistance reduction.

 

At 6 months, mean increase in 6-minute walk test was 83 meters for the denervation group and 15 meters for the sildenafil group (p<0.001).

 

Denervation was also associated with a significant drop in pulmonary resistance compared against sildenafil (p=0001).


Read also: TCT 2018 | PADN-5: Pulmonary Artery Denervation in Pre- and Post-Capillary Pulmonary Hypertension.


Some patients showed worse clinical outcomes during the study, though there were fewer among denervation patients (16.7% vs. 40%; p=0.014).

 

Conclusion

Pulmonary artery denervation was associated with significant hemodynamic and clinical improvement in patients with pulmonary hypertension of different etiology. More studies are necessary to find out more about the efficacy of this technique.

 

Original title: Pulmonary Artery Denervation Significantly Increases 6-Min Walk Distance for Patients with Combined Pre- and Post-Capillary Pulmonary Hypertension Associated with Left Heart Failure. The PADN-5 Study.

Reference: Hang Zhang et al.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.

More articles by this author

TCT 2024 | SIRONA: Randomized Study Comparing Sirolimus-Coated vs Paclitaxel-Coated Balloon Angioplasty in Femoropopliteal Disease

This prospective, randomized, multicenter, investigator-initiated non-inferiority study compared the use of sirolimus-coated balloon (MagicTouch) vs paclitaxel-coated balloon in endovascular treatment.  The primary objective was to...

TCT 2024 | PEERLESS: Mechanical Thrombectomy with FlowTriever vs Catheter-Directed Thrombolysis in Intermediate Risk PTE

Pulmonary embolism (PE) continues to be the third cause of cardiovascular mortality. The current clinical guidelines recommend anticoagulation in intermediate risk patients presenting right...

Atherosclerotic Renal Artery Stenosis: To Revascularize or Not

At long term, atherosclerotic renal artery stenosis (RAS) can lead to hypertension, chronic kidney disease, and cardiac failure. Historically, these patients have been referred...

Endovascular Management of Chronic TEPH: Is Coronary Management Extrapolatable in This Scenario?

Chronic thromboembolic pulmonary hypertension (CTEPH) is a condition that causes significant functional limitation. Its surgical treatment, known as pulmonary endarterectomy (PEA), has improved the...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

TCT 2024 | FAVOR III EUROPA

The study FAVOR III EUROPA, a randomized trial, included 2,000 patients with chronic coronary syndrome, or stabilized acute coronary syndrome, and intermediate lesions. 1,008...

TCT 2024 | TRISCEND II

This randomized study included 400 patients; 267 were treated with EVOQUE valve and 133 with optimal medical treatment (OMT). After one-year follow-up, there were no...

TCT 2024 – ACCESS-TAVI: Comparing Percutaneous Access Closure Strategies After TAVI

Vascular access complications following transcatheter aortic valve implantation (TAVI) remain common. However, few studies compare vascular access closure methods.  Based on the CHOICE-CLOSURE and MASH...